Real-World Effectiveness and Safety of Dotinurad in Chinese Patients with Gout: A Comparative Analysis Authors: Guanqun Yi, Xuechan Huang, Yukai Huang, Zhixiang Huang, Shaoling Zheng, Zhengping Huang, Weiming Deng, Chun Zheng, Tianwang Li Published: 2026 ABSTRACT BackgroundDotinurad, a novel selective uric acid (UA) reabsorption inhibitor, exerts its hypouricemic effect through the selective inhibition of urate transporter 1 (URAT1). The present study aimed to investigate the short-term effectiveness and safety of dotinurad in the treatment of Chinese patients with gout, while also conducting a comparative analysis with febuxostat.MethodsThis retrospective study enrolled 70 consecutive eligible inpatients and outpatients with gout from the Department of Rheumatology and Immunology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, were screened during the period from 1 January 2025 to 30 December 2025. Treatment was prescribed at the discretion of the treating clinician: 35 patients receiving dotinurad and 35 receiving febuxostat. The primary analyses focused on serum uric acid (UA) target attainment (≤ 360 μmol/L or ≤ 300 μmol/L) for patients with dotinurad or febuxostat) and short-term urate-lowering effectiveness after 4 weeks of treatment. Short-term changes in hepatic and renal function parameters were also evaluated.ResultsAfter one month of treatment, the attainment rates for UA ≤ 360 μmol/L in the dotinurad group and the febuxostat group were 60.0% and 45.7%, respectively. The attainment rates for UA ≤ 300 μmol/L were 45.7% and 14.3%, respectively. While baseline UA levels did not differ significantly between the two groups (P = 0.227), a significant difference was observed after 4 weeks of treatment (The serum UA levels at week-4 after treatment in the dotinurad group and febuxostat group were 294.47 ± 19.31 and 380.85 ± 21.43, respectively; P = 0.003). After one month of treatment, significant intergroup differences were observed in the changes from baseline of UA and serum creatinine (SCR) (P = 0.003 and P = 0.029, respectively), whereas no statistically significant intergroup differences were found in the changes from baseline of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (P = 0.761 and P = 0.551, respectively).ConclusionsIt was found that 2 mg/day of Dotinurad was superior to 40 mg/day of febuxostat in achieving serum UA levels ≤ 360 μmol/L or ≤ 300 μmol/L after 4 weeks in Chinese patients with gout and exerted superior short-term urate-lowering effectiveness to febuxostat. Additionally, dotinurad is not associated with a risk of hepatic or renal injury in the short term, whereas febuxostat may increase SCR levels over the short course. The conclusions are only applicable to the clinical medication setting where febuxostat is initiated at a dose of 40 mg in Chinese patients with gout. Key Points In the short-term observation, this study found that 2 mg/day of dotinurad exhibited superior urate-lowering effectiveness compared with 40 mg/day of febuxostat.In the short-term observation at week-4 of treatment, the target attainment rate (UA <360 μmol/L or <300 μmol/L) was higher in patients receiving 2 mg/day of dotinurad relative to those treated with 40 mg/day of febuxostat.Dotinurad is not associated with a risk of hepatic or renal injury in the short term, whereas febuxostat may correlate with an elevated risk of increased SCR levels over the short course. In the short-term observation, this study found that 2 mg/day of dotinurad exhibited superior urate-lowering effectiveness compared with 40 mg/day of febuxostat.In the short-term observation at week-4 of treatment, the target attainment rate (UA <360 μmol/L or <300 μmol/L) was higher in patients receiving 2 mg/day of dotinurad relative to those treated with 40 mg/day of febuxostat.Dotinurad is not associated with a risk of hepatic or renal injury in the short term, whereas febuxostat may correlate with an elevated risk of increased SCR levels over the short course. Introduction Gout is an inflammatory arthritis that arises from hyperuricemia, generally defined as a serum urate concentration exceeding approximately 7 mg/dL. Sustained elevations in serum urate can precipitate the deposition of monosodium urate crystals, thereby inducing inflammatory arthritis [1]— a condition recognized as the most common form of inflammatory arthritis among adults worldwide. The global prevalence of gout has increased markedly since 1990, with an estimated 55.8 million individuals currently affected [2]. This upward trend, evident both in China and internationally, may be associated with increases in population life expectancy [34]. Gout is closely associated with chronic kidney disease (CKD) [25]. Hyperuricemia contributes to the progression of CKD in patients with gout [6]. Additionally, elevated uric acid (UA) levels correlate with a higher incidence of chronic kidney disease [7]. Therefore, urate-lowering therapy is a critical component of gout management. While febuxostat, allopurinol (uric acid synthesis inhibitors), and benzbromarone (a uricosuric agent) are widely prescribed for urate lowering, their use is nevertheless associated with certain limitations. Febuxostat, a xanthine oxidase inhibitor, has been associated with an increased risk of cardiovascular events [8]. Therefore, it should be used with caution in patients with cardiovascular disease [29] and necessitates dynamic monitoring of indicators such as cardiac enzymes. Additionally, febuxostat may cause liver dysfunction [10]. In Han Chinese patients, allopurinol is associated with a higher risk of severe cutaneous adverse reactions [11]. HLA-B*5801 allele screening is required prior to initiation, and allopurinol is contraindicated in patients who carry this allele. Benzbromarone, a urate-lowering agent, has been associated with safety concerns, particularly hepatotoxicity [12]. It is linked to severe hepatitis and other forms of liver injury [10]. Furthermore, benzbromarone may induce renal accumulation of uremic toxins by inhibiting ATP-binding cassette transporter G2 (ABCG2), the primary transporter for indoxyl sulfate and other uremic toxins. By inhibiting intestinal uric acid excretion, it may also contribute to excessive uric acid levels in the kidneys [13], thereby potentially causing renal damage. However, dotinurad is a novel selective UA reabsorption inhibitor [10]. It promotes UA excretion by selectively inhibiting urate transporter 1 (URAT1), a transporter responsible for UA reabsorption in the renal proximal tubules [14]. Importantly, dotinurad does not inhibit ABCG2. Dotinurad was approved in Japan in 2020 for the treatment of hyperuricemia and gout [2]. To date, nearly all clinical trials and real-world studies of dotinurad have been conducted in Japanese populations. In December 2025, the findings from a randomized, multicenter, double-blind Phase III clinical trial conducted in China were reported, evaluating the efficacy and safety of dotinurad in patients with gout [2]. The results demonstrated that at week-12, the uric acid target attainment rate with 2 mg of dotinurad once daily was noninferior to that with 40 mg of febuxostat once daily. At week-24, the target attainment rate with 4 mg of dotinurad once daily was significantly higher than that with 40 mg of febuxostat once daily [2]. Dotinurad was well tolerated in Chinese patients, and no new safety signals were observed [2]. As randomized controlled investigations (RCT), the original Phase III RCT have provided high-grade evidence for the efficacy of dotinurad in Chinese patients with gout. Nevertheless, RCTs adopt strict eligibility criteria, standardized intervention protocols and intensive follow-up schedules, which differ substantially from routine clinical practice. RCTs frequently exclude complex patients with multisystem comorbidities, a population commonly encountered in daily clinical settings, and the rigid dosing regimens applied in RCTs cannot be directly generalized to routine clinical management. However, real-world research can overcome the limitations of RCTs and is particularly suitable for early post-marketing evaluation of novel medications. Given dotinurad was launched in China in July 2025 and published real-world evidence in Chinese patients remains limited. Clinicians have limited clinical experience with newly launched drugs in the early post-marketing period. Therefore, this single-center retrospective real-world study aims to compare the short-term effectiveness and safety of dotinurad versus febuxostat under routine clinical practice, so as to supplement real-world evidence beyond that derived from RCT. Simultaneously, this research focuses on the clinical application of dotinurad within the first year following its domestic launch in China, which can provide real-world evidence to guide clinical medication for broader patient groups. Methods Study Design This is a single-center retrospective real-world study. All eligible gout inpatients and outpatients consecutively were treated in the Department of Rheumatology and Immunology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University from 1 January 2025 to 30 December 2025. The detailed inclusion and exclusion criteria are supplemented below. Inclusion criteria: ①meeting the 2015 ACR/EULAR gout classification criteria [15] and ②aged ≥ 18 years, with both male and female patients eligible. The exclusion criteria were as follows: ①secondary hyperuricemia induced by nephropathy, hematological diseases, chemotherapy, medications, or other causes; ②insufficient medication duration of less than 4 weeks; ③missing or incomplete laboratory data at baseline and week 4; ④complicated severe hepatic or renal dysfunction, psychiatric disorders or malignant tumors; ⑤receipt of other urate-lowering agents besides dotinurad or febuxostat; and ⑥loss to follow-up. Study Subjects This study included 70 eligible adult patients diagnosed with gout in the Department of Rheumatology and Immunology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, between January 2025 and December 2025. The detailed screening process for study participants is presented in Fig. 1. The study was conducted in accordance with the Declaration of Helsinki. Owing to its retrospective nature, informed consent was waived. Ethical approval was obtained from the Institutional Review Board of The Affiliated Guangdong Second Provincial General Hospital of Jinan University (approval no. 2026-KY-KZ-269-01, no. 2025-KY-KZ-480-02).Fig. 1Flow chart of study subject screening, exclusion and enrollment Flow chart of study subject screening, exclusion and enrollment Patient Grouping Treatment was prescribed at the discretion of the treating clinician: the dotinurad group (n = 35) received 2 mg of dotinurad once daily for urate-lowering therapy, and the febuxostat group (n = 35) received 40 mg of febuxostat once daily. The selection between dotinurad and febuxostat was entirely based on individualized comprehensive clinical judgment by attending physicians, taking into account patient indications, contraindications, and patients’ voluntary preferences. Both agents were equally available for prescription at our institution without mandatory standardized screening algorithms, and both are recommended as first-line urate-lowering therapies for gout. The two groups were not enrolled during identical enrollment periods. Dotinurad was officially launched in China on 1 July 2025; hence, patients in the dotinurad group were enrolled exclusively between 1 July and 30 December 2025. By contrast, patients in the febuxostat group were consecutively enrolled from 1 January to 30 December 2025. Despite the differing enrollment windows, a unified endpoint for outcome observation was applied to both groups: effectiveness and safety were evaluated after 4 consecutive weeks of regular consistent medication. Data Collection Data collected included patient demographics (gender, age, and comorbidities, disease duration, presence of tophi) as well as laboratory parameters. The latter comprised serum levels of UA, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and serum creatinine (SCR), and estimated Glomerular Filtration Rate (eGFR), measured at baseline and after one month of treatment. To evaluate short-term effectiveness and safety, serum levels of UA, ALT, AST, and SCR were analyzed at baseline and after 1 month of treatment. eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${186 } \times {\text{ SCR}}^{{ - {1}.{154}}} \times {\mathrm{age}}^{{ - 0.{2}0{3}}}$$\end{document}186×SCR-1.154×age-0.203 Definition of Indicators Outcome definition: The primary outcome was the proportion of patients who achieved the predefined serum urate targets (UA ≤ 360 μmol/L or ≤ 300 μmol/L) after 4 weeks of regular medication. The secondary outcomes included the serum urate level at week 4 and the mean change in serum urate from baseline to week 4. All effectiveness assessments were strictly performed at the 4-week follow-up after continuous treatment. Serum urate target threshold: In accordance with 2012 ACR Gout Management Guidelines [16], the general target for all gout patients was set at < 6 mg/dL (360 μmol/L), and a stricter target of < 5 mg/dL (300 μmol/L) was applied to patients with tophi. Therefore, the serum urate control targets in this study were defined as < 360 μmol/L and < 300 μmol/L, respectively. The exact time window used for the post-treatment assessment: For the post-treatment evaluation time window, all laboratory parameters were uniformly collected at the week-4 follow-up after consistent medication adherence for outcome assessment. Adverse events: this was a retrospective observational study based on electronic medical records, and no prospective and standardized active collection of adverse events was conducted. Adverse events were extracted only from patients’ self-reported symptoms and abnormal laboratory results (such as liver and renal function) documented in routine medical records during the 4-week observation period. Laboratory abnormalities annotated with clinical significance by attending physicians were regarded as potential adverse events. Asymptomatic mild laboratory abnormalities without clinical significance were excluded from adverse events. Statistical Analysis All statistical analyses in the present study were performed using IBM SPSS Statistics version 25.0. Normally distributed continuous variables were expressed as mean ± standard deviation (SD), while non-normally distributed continuous variables were presented as median (25th-75th percentile). Within-subject pretreatment and post-treatment comparisons were performed using t-tests or Wilcoxon rank-sum tests, as appropriate. Categorical variables were analyzed using the chi-square test or Fisher’s exact test. Analysis of covariance (ANCOVA) was used to compare the changes in laboratory indicators at week 4 after treatment between the two groups, adjusting for potential baseline confounders: presence of tophi and comorbidities, age, gout duration, baseline serum UA, baseline SCR, baseline ALT, baseline AST, and eGFR. Adjusted marginal means and Bonferroni-corrected P values were presented for intergroup comparisons in the present study. The significance level was set at a two-sided P value < 0.05, and all hypothesis tests were two-sided. A P-value of < 0.05 was considered statistically significant. Results: Comparison of Sociodemographic and Clinical Characteristics Between the Two Groups Baseline characteristics of the two groups are summarized in Table 1. There were no statistically significant differences in age, sex, or comorbidities between the groups (P>0.05), whereas disease duration, presence of tophi and eGFR differed significantly (P<0.05).Table 1Baseline characteristics of the study patientsCharacteristicsDotinurad (n = 35)Febuxostat (n = 35)P-valueAge (mean ± SD)43.63 ± 14.2147.80 ± 15.650.247Sex (Male, %)100 %100 %-Disease duration (years)7.02 ± 6.069.03 ± 3.870.018Presence of tophi22 (62.86)30 (85.71%)0.029eGFR83.95 ± 21.8695.29 ± 20.970.039ComorbiditiesCardiovascular diseases (n)790.603Cerebrovascular diseases (n)111.000Diabetes (n)340.726Hyperlipidemia (n)230.724eGFR estimated Glomerular Filtration Rate; eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula: 186 × SCR−1.154 × age−0.203 Table 1Baseline characteristics of the study patientsCharacteristicsDotinurad (n = 35)Febuxostat (n = 35)P-valueAge (mean ± SD)43.63 ± 14.2147.80 ± 15.650.247Sex (Male, %)100 %100 %-Disease duration (years)7.02 ± 6.069.03 ± 3.870.018Presence of tophi22 (62.86)30 (85.71%)0.029eGFR83.95 ± 21.8695.29 ± 20.970.039ComorbiditiesCardiovascular diseases (n)790.603Cerebrovascular diseases (n)111.000Diabetes (n)340.726Hyperlipidemia (n)230.724eGFR estimated Glomerular Filtration Rate; eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula: 186 × SCR−1.154 × age−0.203 Baseline characteristics of the study patients eGFR estimated Glomerular Filtration Rate; eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) formula: 186 × SCR−1.154 × age−0.203 Comparison of Effectiveness and Safety Within Each Group Before and After Treatment Table 2 presents the within-group comparisons of UA and liver and kidney function parameters (including ALT, AST, and SCR) at baseline and after one month of treatment for both groups. In the dotinurad group, UA levels decreased significantly from baseline after 4 weeks of treatment (P<0.001), while no statistically significant changes were observed in liver and kidney function indicators (ALT, AST, and SCR) (P > 0.05).Table 2Comparison of short-term effectiveness and safety outcomes within each group at baseline and 4 weeksUASCRALTASTDotinuradBaseline524.95 ± 97.1595.10 (80.40, 101.10)28 (23, 61)26 (22, 34)4 weeks327.49 ± 110.4089.30 (81.40, 100.20)33 (20, 50)24 (20,30)P-value0.0000.5690.5570.437FebuxostatBaseline490.37 ± 136.7183.56 ± 14.7122 (16, 30)21 (16, 24)4 weeks377.63 ± 86.0695.01 ± 21.0421 (19, 31.52)23.8 ± 5.79P-value0.0000.0110.4700.030UA uric acid, unit: μmol/L; SCR serum creatinine, unit: μmol/L; ALT serum alanine aminotransferase, unit: U/L; AST aspartate aminotransferase, unit: U/L; values were presented as mean ± SD or median (25th–75th percentile). Table 2Comparison of short-term effectiveness and safety outcomes within each group at baseline and 4 weeksUASCRALTASTDotinuradBaseline524.95 ± 97.1595.10 (80.40, 101.10)28 (23, 61)26 (22, 34)4 weeks327.49 ± 110.4089.30 (81.40, 100.20)33 (20, 50)24 (20,30)P-value0.0000.5690.5570.437FebuxostatBaseline490.37 ± 136.7183.56 ± 14.7122 (16, 30)21 (16, 24)4 weeks377.63 ± 86.0695.01 ± 21.0421 (19, 31.52)23.8 ± 5.79P-value0.0000.0110.4700.030UA uric acid, unit: μmol/L; SCR serum creatinine, unit: μmol/L; ALT serum alanine aminotransferase, unit: U/L; AST aspartate aminotransferase, unit: U/L; values were presented as mean ± SD or median (25th–75th percentile). Comparison of short-term effectiveness and safety outcomes within each group at baseline and 4 weeks UA uric acid, unit: μmol/L; SCR serum creatinine, unit: μmol/L; ALT serum alanine aminotransferase, unit: U/L; AST aspartate aminotransferase, unit: U/L; values were presented as mean ± SD or median (25th–75th percentile). In the febuxostat group, uric acid levels also showed a significant reduction from baseline to 4 weeks of treatment(P<0.001). Although ALT levels did not change significantly (P > 0.05), both SCR and AST levels demonstrated statistically significant increases compared with baseline (P = 0.011, P = 0.030, respectively). Urate Target Attainment Rates Between the Two Groups after 4 Weeks of Treatment After 4 weeks of treatment, the attainment rates for UA ≤ 360 μmol/L in the dotinurad group and the febuxostat group were 60.0 % and 45.7 %, respectively. The attainment rates for UA ≤ 300 μmol/L were 45.7 % and 14.3%, respectively (Fig. 2).Fig. 2Urate target attainment rates between the two groups. UA uric acid, unit: μmol/L Urate target attainment rates between the two groups. UA uric acid, unit: μmol/L Comparison of Uric Acid Levels Between the Two Groups After 4 Weeks of Treatment Analysis of UA levels at week-4 post-treatment between the two groups was performed using ANCOVA, with adjustment for potential baseline confounding factors including presence of tophi, comorbidities, age, gout duration, baseline serum UA, baseline SCR, baseline ALT, baseline AST, and baseline eGFR; a significant difference in UA distribution was observed between the two groups at week-4 post-treatment (P = 0.003) (Table 3).Table 3Uric Acid Levels at Baseline and After 4 Weeks of TreatmentBaselineWeek-4DotinuradFebuxostatP-valueDotinuradFebuxostatFP-valueUA524.95 ± 97.15490.37 ± 136.710.227294.47 ± 19.31380.85 ± 21.439.5330.003UA uric acid, unit: μmol/L values were presented as mean ±SD or median (25th-75th percentile) Table 3Uric Acid Levels at Baseline and After 4 Weeks of TreatmentBaselineWeek-4DotinuradFebuxostatP-valueDotinuradFebuxostatFP-valueUA524.95 ± 97.15490.37 ± 136.710.227294.47 ± 19.31380.85 ± 21.439.5330.003UA uric acid, unit: μmol/L values were presented as mean ±SD or median (25th-75th percentile) Uric Acid Levels at Baseline and After 4 Weeks of Treatment UA uric acid, unit: μmol/L values were presented as mean ±SD or median (25th-75th percentile) Changes in Uric Acid, Liver and Renal Function Parameter at Week-4 Post-Treatment Between the Two Groups ANCOVA was similarly applied to further compare the changes from baseline in UA, hepatic and renal function parameters at week-4 post-treatment between the two groups, with adjustment for potential confounders (including presence of tophi, comorbidities, age, gout duration, baseline serum UA, baseline SCR, baseline ALT, baseline AST, and baseline eGFR). Significant intergroup differences were observed in the changes from baseline of UA and SCR (P = 0.003 and P = 0.029, respectively), whereas no statistically significant intergroup differences were found in the changes from baseline of liver function markers (including ALT and AST) (P = 0.761 and P = 0.551, respectively) (Table 4 and Fig.3).Table 4Changes in UA and liver/kidney function parameters from baseline to week-4 post-treatmentDotinuradFebuxostatFP-valueUA−213.19 ± 19.31−126.81 ± 21.439.5330.003SCR0.82 ± 3.2511.34 ± 3.614.7090.029ALT−0.06 ± 3.711.56 ± 4.110.0930.761AST0.22 ± 1.421.45 ± 1.570.3590.551UA uric acid, unit: μmol/L; SCR serum creatinine, unit: μmol/L; ALT serum alanine aminotransferase, unit: U/L; AST aspartate aminotransferase, unit: U/L values were presented as mean ±SDFig. 3Changes in UA and liver/kidney function parameters from baseline to week-4 post-treatment: comparison between the two groups. A Changes in UA. B Changes in liver and kidney function parameters. UA uric acid; SCR serum creatinine; ALT serum alanine aminotransferase; AST aspartate aminotransferase. Table 4Changes in UA and liver/kidney function parameters from baseline to week-4 post-treatmentDotinuradFebuxostatFP-valueUA−213.19 ± 19.31−126.81 ± 21.439.5330.003SCR0.82 ± 3.2511.34 ± 3.614.7090.029ALT−0.06 ± 3.711.56 ± 4.110.0930.761AST0.22 ± 1.421.45 ± 1.570.3590.551UA uric acid, unit: μmol/L; SCR serum creatinine, unit: μmol/L; ALT serum alanine aminotransferase, unit: U/L; AST aspartate aminotransferase, unit: U/L values were presented as mean ±SD Changes in UA and liver/kidney function parameters from baseline to week-4 post-treatment UA uric acid, unit: μmol/L; SCR serum creatinine, unit: μmol/L; ALT serum alanine aminotransferase, unit: U/L; AST aspartate aminotransferase, unit: U/L values were presented as mean ±SD Changes in UA and liver/kidney function parameters from baseline to week-4 post-treatment: comparison between the two groups. A Changes in UA. B Changes in liver and kidney function parameters. UA uric acid; SCR serum creatinine; ALT serum alanine aminotransferase; AST aspartate aminotransferase. Discussion This retrospective study aimed to evaluate the short-term effectiveness and safety of dotinurad in Chinese patients with gout in a real-world setting. We retrospectively analyzed UA levels and liver and kidney function parameters in 35 gout patients treated with 2 mg of dotinurad once daily and 35 patients treated with 40 mg of febuxostat once daily, assessed at baseline and after four weeks of treatment. This study demonstrated that dotinurad exerted superior short-term urate-lowering effectiveness and achieved better early serum uric acid control compared with febuxostat among Chinese patients with gout. These findings are consistent with the results of phase III clinical trials conducted domestically and overseas. A domestic multicenter phase III trial further verified that the rate of UA target attainment (≤ 360 μmol/L) at week-12 was significantly higher in patients receiving dotinurad than those treated with febuxostat [2], while a Japanese phase III trial reported that dotinurad rapidly reduced serum uric acid levels as early as 2 weeks after treatment initiation [10]. Distinct safety profiles were observed between the two groups before adjustment for baseline covariates: mild abnormalities in renal function indicators were detected in the febuxostat group, whereas no obvious fluctuations in hepatic or renal parameters were noted in the dotinurad group. Given the retrospective cohort design of the present study, inherent intergroup imbalance existed in baseline characteristics including presence of tophi, comorbidities, variables including age, gout duration, baseline serum UA, baseline SCR, baseline ALT, baseline AST, and baseline eGFR. ANCOVA was performed to adjust for the above confounding factors to objectively compare the short-term effectiveness and safety profiles of the two agents. After confounding adjustment, the prominent early urate-lowering advantage of dotinurad remained robust. Meanwhile, this study found that febuxostat is associated with an elevated risk of renal impairment, whereas dotinurad carries no risk of renal injury, which can be explained by the fundamentally distinct mechanisms of action of the two drugs. ABCG2 is expressed in the intestinal epithelium and mediates the excretion of intestinal uric acid and indoxyl sulfate (a uremic toxin linked to the progression of chronic kidney disease) [1718]. Febuxostat potently inhibits the transport function of ABCG2 [19], which may not only reduce intestinal uric acid excretion and compromise the overall magnitude of UA reduction, but also disrupt indoxyl sulfate (intrarenal toxin) transport, serving as one potential mechanism underlying SCR elevation observed in some treated patients with febuxostat. Similar reports documenting creatinine elevation and impaired renal function linked to febuxostat have been published in previous studies. A 2019 post-marketing study [20] entitled “Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study” stated that the reporting frequency of febuxostat-related acute renal failure was 5.7-fold higher than that of other medications. By contrast, dotinurad is a highly selective URAT1 inhibitor. It suppresses tubular urate reabsorption to augment urinary uric acid excretion and reduce serum UA levels, while having no inhibitory activity against ABCG2. This characteristic maintains the excretion of indoxyl sulfate and may slow the deterioration of renal function [19]. The study by Kurihara O has demonstrated that dotinurad not only reduces serum uric acid but also ameliorates renal function among patients with severe renal insufficiency [21]; additionally, the study by Kamijo Y reported that dotinurad improves hepatic and renal biomarkers in hyperuricemic patients concurrent with fatty liver disease [22]. Furthermore, by reducing renal tubular reabsorption of UA, dotinurad may exert beneficial effects on renal outcomes [23]. Conversely, no notable renal function improvement trend was detected in our dotinurad group, likely owing to the 4-week limited treatment course that has not reached the window for measurable renal benefits, whereas prior studies by Kurihara O and Kamijo Y conducted evaluations after ≥ 3 months of therapy. Regarding hepatic tolerability, adjusted analyses revealed that short-term treatment with either drug failed to trigger clinically meaningful liver damage. Consistent with previous literature reports, researchers in a study titled “A Single‑ and Multiple‑Dose Study to Characterize the Pharmacokinetics and Safety of dotinurad in Healthy Chinese Adults” reported that no specific safety concerns emerged during dotinurad administration in healthy Chinese adults [24]. The disparities in short-term urate-lowering potency and renal tolerability between the two drugs provide clinical evidence for individualized gout management. Dotinurad may deliver greater clinical benefits for patients who require rapid UA target attainment. However, the results observed herein cannot be directly extrapolated to patients initiated on 80 mg of febuxostat. The 80 mg initial febuxostat dose was used in the landmark Western phase III trials, namely the Allopurinol and Placebo-Controlled Efficacy Study of Febuxostat (APEX) and the Febuxostat Allopurinol Controlled Trial (FACT) [2526], which was not suitable for routine Chinese clinical practice owing to ethnic and regional disparities. Chinese guidelines recommend a 40 mg starting dose with dose adjustment at week 4 guided by serum urate levels, as this balanced approach optimizes therapeutic effectiveness while minimizing risks of Drug reation with eosinophilia and systemic symptoms (DRESS) and other severe adverse reactions. Utilizing the 40 mg initial regimen as our comparator conforms to the methodological logic of Chinese real-world research by mirroring standard Chinese prescribing patterns. This study has several limitations. First, as a single-center, retrospective observational analysis, it may be subject to patient selection bias, which limits the generalizability of our findings. Second, we explained that propensity score matching (PSM) was not performed owing to limited sample size, and baseline confounders were adjusted using ANCOVA only. We acknowledged that statistical adjustment and control of confounders could not completely eliminate potential impacts of seasonal variations and shifts in routine clinical practice on the study results. We proposed that future prospective studies with fully synchronized enrollment periods would help validate the findings of the present research. Third, the limited sample size restricts the generalizability of our results. The follow-up period was limited to 4 weeks in this study and only provided preliminary short-term observational evidence from real-world clinical practice. It cannot be generalized to long-term therapeutic effects, sustained urate-lowering control or delayed adverse events. Long-term follow-up studies with large sample size are warranted in subsequent research to evaluate the durability of urate-lowering effectiveness and long-term safety profiles. Fourth, treatment assignment of urate-lowering agents relied on discretionary clinical judgment rather than randomization. Differential prescribing patterns between novel and conventional urate-lowering agents represent an inherent limitation of retrospective observational real-world studies. ANCOVA was performed to balance potential baseline confounding factors and minimize their impact on comparative outcomes. Fifth, female sex was not defined as an exclusion criterion in this study, and the all-male composition of the cohort merely reflected the natural demographic distribution of patients presenting in routine clinical practice, rather than deliberate exclusion of female patients. The absence of female participants restricts the generalizability of our study findings. Conclusions Dotinurad at a dose of 2 mg once daily demonstrated significant therapeutic short-term effectiveness in lowering UA, achieving a superior rate of target attainment (≤ 360 μmol/L or ≤ 300 μmol/L) compared with febuxostat. Furthermore, dotinurad treatment was not associated with an increased risk of liver or kidney dysfunction. Owing to divergent initial febuxostat dosing strategies adopted domestically versus overseas, the findings of this study are only generalizable to Chinese gout patients treated with an initial febuxostat dose of 40 mg, and cannot be extended to populations receiving an immediate 80 mg starting dose.